In short
TransMedics Group, Inc. (TMDX) has revenue up 37.1% to $605.5M and gross profit up 38.4% to $362.8M year on year. Its net margin is 31.4% and gross margin 59.9%, and it trades at 17.9× trailing earnings. Fisclear flags 1 medium-severity risk and no high-severity ones. How we calculate this
Valuation
HealthcareLive · Yahoo FinancePrice
$85.25
$3.0B
26.9x
52-Week Range
Decision Context
Beneish M-Score flags possible earnings quality concerns. The financial metrics above warrant additional scrutiny of reported figures.
Based on filing period ending Sept 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
Fed Funds Rate
3.88%
Accommodative
10-Year Treasury
5.13%
2026-10-01
Unemployment
4.2%
Near full employment
CPI Index
336.3
2026-09-01
M2 Money Supply
$23.4T
2026-09-01
The Federal Funds rate stands at 3.88% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 5.13%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.2%; Industrial production index is at 104.0; M2 money supply is $23.4T; CPI index stands at 336.3.
SWOT Analysis — TMDX
Inflationary BoomStrengths
Net Income: $190.3M (+436.6% YoY) — Profit grew 437% — the company kept more of each dollar earned.
EPS (Diluted): $4.87 (+382.2% YoY) — Earnings per share rose 382% — each share earned more.
Operating Cash Flow: $192.8M (+295.1% YoY) — Operating cash flow grew 295% — the business generated more cash from day-to-day operations.
Gross Profit: $362.8M (+38.4% YoY) — Gross profit rose 38% — the spread between revenue and direct costs improved.
Revenue: $605.5M (+37.1% YoY) — Revenue grew 37% — the company sold more goods or services than the prior year.
Weaknesses
Beta of 2.10x — this stock moves significantly more than the broader market, amplifying both gains and drawdowns.
Opportunities
No clear opportunities identified at this time.
Threats
Stock is within 10% of its 52-week low (60.10) — the market may be pricing in significant risk or sector weakness.
Year-over-Year Changes
Net Income
$190.3M
was $35.5M
Profit grew 437% — the company kept more of each dollar earned.
EPS (Diluted)
$4.87
was $1.01
Earnings per share rose 382% — each share earned more.
Operating Cash Flow
$192.8M
was $48.8M
Operating cash flow grew 295% — the business generated more cash from day-to-day operations.
Gross Profit
$362.8M
was $262.1M
Gross profit rose 38% — the spread between revenue and direct costs improved.
Revenue
$605.5M
was $441.5M
Revenue grew 37% — the company sold more goods or services than the prior year.
Risk Flags
0 high · 1 medium · 1 low- ◈ Medium
Stock is within 10% of its 52-week low (60.10) — the market may be pricing in significant risk or sector weakness.
- ○ Low
Beta of 2.10x — this stock moves significantly more than the broader market, amplifying both gains and drawdowns.
Technical Signals
Daily closes · 1-year dataTransMedics Group, Inc.: common questions
Is TransMedics Group, Inc. profitable?
Yes. TransMedics Group, Inc. made a net profit of $190M in its latest fiscal year (fiscal 2025), a net margin of 31.4%.
Is TransMedics Group, Inc.'s revenue growing?
Yes. Revenue grew 37.1% year on year, to $605.5M.
What is TransMedics Group, Inc.'s P/E ratio?
TransMedics Group, Inc. trades at 23.2× its trailing twelve-month earnings. In other words, the share price is about 23 times the profit per share the company earned over the past year.
Does TransMedics Group, Inc. pay a dividend?
No dividend is currently expected from TransMedics Group, Inc., according to the latest market data.
What are the main risks for TransMedics Group, Inc.?
Fisclear's checks flag 1 medium- or high-severity risk. The most serious: Stock is within 10% of its 52-week low (60.10) — the market may be pricing in significant risk or sector weakness.
Answers are generated from the figures in this report (updated 6 Nov 2026). Information, not investment advice.
Latest News
via FinnhubFiling History — TMDX
Get the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade TMDX
Links open broker research pages. Not an endorsement or recommendation.
Research TransMedics Group, Inc.
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.